Click to view our accessibility statement Delivering on HopeTM ABOUT US PATIENTS & FAMILIES PRODUCTS PIPELINE CAREERS INVESTORS Contact Us News & Events NEWS MONDAY NOVEMBER 22, 2021 NEUROCRINE BIOSCIENCES AND SOSEI HEPTARES ANNOUNCE COLLABORATION TO DEVELOP NOVEL MUSCARINIC RECEPTOR AGONISTS FOR SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 Sosei Heptares receives US$100 million upfront, ongoing R&D funding, and up to US$2.6 billion in TUESDAY NOVEMBER 09, 2021 NEUROCRINE BIOSCIENCES TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer will present at MONDAY NOVEMBER 01, 2021 NEUROCRINE BIOSCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS INGREZZA® (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021 . MONDAY NOVEMBER 01, 2021 NEUROCRINE BIOSCIENCES PRESENTS NEW INGREZZA® (VALBENAZINE) DATA AT PSYCH CONGRESS 2021 SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021. SATURDAY OCTOBER 16, 2021 NEUROCRINE BIOSCIENCES TO PRESENT ONGENTYS® (OPICAPONE) AND INGREZZA® (VALBENAZINE) DATA AT THE AMERICAN NEUROLOGICAL ASSOCIATION 2021 VIRTUAL ANNUAL MEETING SAN DIEGO , Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual EVENTS WEDNESDAY MARCH 13, 2019 MARCH 13, 2019 11:15 AM EDT : NEUROCRINE BIOSCIENCES AT BARCLAYS GLOBAL HEALTHCARE CONFERENCE Open Webcast TUESDAY MARCH 12, 2019 MARCH 12, 2019 10:00 AM EDT : NEUROCRINE BIOSCIENCES AT COWEN 39TH ANNUAL HEALTH CARE CONFERENCE Open Webcast TUESDAY FEBRUARY 05, 2019 FEBRUARY 5, 2019 4:30 PM EST : Q4 AND YEAR-END 2018 NEUROCRINE BIOSCIENCES EARNINGS CONFERENCE CALL Open Webcast TUESDAY JANUARY 29, 2019 JANUARY 29, 2019 8:00 AM EST : NEUROCRINE BIOSCIENCES UPDATE Open Webcast MONDAY JANUARY 07, 2019 JANUARY 7, 2019 5:30 PM EST : NEUROCRINE BIOSCIENCES AT THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Open Webcast ABOUT US About Neurocrine Leadership Team Culture & Values Diversity, Equity & Inclusion News & Events Webcasts & Presentations Contact Us ©2021 Neurocrine Biosciences, Inc. All Rights Reserved. Privacy Policy Cookie Policy Terms & Conditions Accessibility Sitemap